Ocular Surface Ion Transport and Dry Eye Disease.

IF 0.9 Q4 OPHTHALMOLOGY Current Ophthalmology Reports Pub Date : 2022-12-01 Epub Date: 2022-10-20 DOI:10.1007/s40135-022-00295-3

Ethan S Lindgren, Onur Cil, Alan S Verkman, Neel D Pasricha

{"title":"Ocular Surface Ion Transport and Dry Eye Disease.","authors":"Ethan S Lindgren, Onur Cil, Alan S Verkman, Neel D Pasricha","doi":"10.1007/s40135-022-00295-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: To review the role of ocular surface epithelial (corneal and conjunctival) ion transporters in the pathogenesis and treatment of dry eye disease (DED).Recent findings: Currently, anti-inflammatory agents are the mainstay of DED treatment, though there are several agents in development that target ion transport proteins on the ocular surface, acting by pro-secretory or anti-absorptive mechanisms to increase the tear fluid Film volume. Activation or inhibition of selected ion transporters can alter tear fluid osmolality, driving water transport onto the ocular surface via osmosis. Several ion transporters have been proposed as potential therapeutic targets for DED, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs), and the epithelial sodium channel (ENaC).Summary: Ocular surface epithelial cell ion transporters are promising targets for pro-secretory and anti-absorptive therapies of DED.","PeriodicalId":10836,"journal":{"name":"Current Ophthalmology Reports","volume":"10 1","pages":"188-197"},"PeriodicalIF":0.9000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10783585/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Ophthalmology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40135-022-00295-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To review the role of ocular surface epithelial (corneal and conjunctival) ion transporters in the pathogenesis and treatment of dry eye disease (DED).

Recent findings: Currently, anti-inflammatory agents are the mainstay of DED treatment, though there are several agents in development that target ion transport proteins on the ocular surface, acting by pro-secretory or anti-absorptive mechanisms to increase the tear fluid Film volume. Activation or inhibition of selected ion transporters can alter tear fluid osmolality, driving water transport onto the ocular surface via osmosis. Several ion transporters have been proposed as potential therapeutic targets for DED, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs), and the epithelial sodium channel (ENaC).

Summary: Ocular surface epithelial cell ion transporters are promising targets for pro-secretory and anti-absorptive therapies of DED.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

眼表面离子迁移与干眼症

综述目的：回顾眼表上皮（角膜和结膜）离子转运体在干眼症（DED）发病机制和治疗中的作用：目前，抗炎药物是治疗干眼症的主要药物，但也有几种药物正在研发中，这些药物以眼表面的离子转运蛋白为靶点，通过促进分泌或抗吸收机制增加泪液膜容量。激活或抑制特定的离子转运体可改变泪液渗透压，通过渗透作用将水分转运到眼表。摘要：眼表上皮细胞离子转运体是促进分泌和抗吸收治疗 DED 的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Ophthalmology Reports Medicine-Ophthalmology

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： This journal aims to offer expert review articles on the most significant recent developments in the field of ophthalmology. By providing clear, insightful, balanced contributions, the journal intends to serve those who diagnose, treat, manage, and prevent ocular conditions and diseases. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include age-related macular degeneration; diabetic retinopathy; dry eye syndrome; glaucoma; pediatric ophthalmology; ocular infections; refractive surgery; and stem cell therapy.